Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Francis Kang

Vascular & Interventional Radiology Aurora, CO Medical Doctor

NPI 1831517804 CMS profile 11300295

13001 E 17Th Pl, University Of Colorado School Of Medicine Gme, Aurora, CO 80045

Open in the dashboard

General payments

$43,982

191 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Francis Kang of Aurora, CO is reported in the CMS Open Payments database as having received $43,982 across 191 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,510 59
2024 General $10,691 61
2023 General $6,522 47
2022 General $1,696 18
2021 General $564 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Francis Kang
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Francis Kang were reported at $24,510. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Francis Kang Vascular & Interventional Radiology median Middle half National median
2019 $0 $422 $125–$1,555 $163
2020 $0 $200 $68–$652 $114
2021 $564 $280 $99–$866 $132
2022 $1,696 $433 $137–$1,497 $149
2023 $6,522 $506 $152–$2,019 $160
2024 $10,691 $556 $175–$1,930 $164
2025 $24,510 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Surefire Medical, Inc. $18,184 41 payments
  2. Sirtex Medical Inc $7,518 13 payments
  3. Inari Medical, Inc. $5,924 33 payments
  4. Penumbra, Inc. $5,701 28 payments
  5. Boston Scientific Corporation $4,627 46 payments
  6. Stryker Corporation $579 7 payments
  7. Balt USA, LLC $341 6 payments
  8. Medtronic, Inc. $270 2 payments
  9. Okami Medical, Inc. $256 2 payments
  10. Imperative Care, INc $219 2 payments
  11. Other $364 11 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $14,300 3 payments
  2. Food and Beverage $13,815 163 payments
  3. Travel and Lodging $8,817 21 payments
  4. Honoraria $7,050 4 payments
Products named General payments · program years 2021–2025
  1. TRINAV INFUSION SYSTEM $18,184 41 payments
  2. LAVA LES (Liquid Embolic System) $6,647 2 payments
  3. FLOWTRIEVER CATHETER, S $6,571 40 payments
  4. CT THROMBECTOMY SYSTEM KIT $5,593 30 payments
  5. Indigo System $5,012 25 payments
  6. TheraSphere Y90 Glass Microspheres 10 GBq $2,624 11 payments
  7. SIR-Spheres Microspheres $871 11 payments
  8. Smart Coil $669 2 payments
  9. Prestige Coil System $341 6 payments
  10. General - Embolics $322 4 payments
  11. Other $2,393 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 165 billing codes

Paid by Medicare

$111,685

Of which drugs: $427

Medicare patients

725

Average age 71

Services billed

5,596

376 women, 349 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 44%
Ischemic heart disease 39%
Chronic kidney disease 39%
Cancer 33%
Heart failure 29%
Atrial fibrillation 28%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 35 3,750 $390

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

191 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record